Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
MCED testing has the potential to increase detection of cancer at earlier stages. As MCED testing is a new technology, there are few data on the diagnostic journeys patients undergo following testing. We observed that for most patients, CSO prediction-directed workups were efficient, leading to diagnostic resolution after initial evaluation.
Authors
- Margarita Lopatin (ORCID: https://orcid.org/0009-0005-7331-5577)
- Lincoln Nadauld (ORCID: https://orcid.org/0000-0002-1935-4998)
- Christina A. Dilaveri (ORCID: https://orcid.org/0009-0007-0875-8253)
- Robert Reid (ORCID: https://orcid.org/0009-0008-6890-6833)
- Charles H. McDonnell (ORCID: https://orcid.org/0009-0000-2415-3923)
- Karen Chung (ORCID: https://orcid.org/0000-0003-4170-8390)
- Rita Shaknovich
- Catherine R. Marinac (ORCID: https://orcid.org/0000-0002-9128-3012)
- Deborah Schrag (ORCID: https://orcid.org/0000-0002-4334-5717)
- Eric T. Fung (ORCID: https://orcid.org/0009-0008-2060-8618)
- Eric A. Klein
Institutions
- Intermountain Healthcare (US)
- Sutter Health (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Utah Tech University (US)
- Kettering University (US)
- Sutter Institute for Medical Research (US)
- Menlo School (US)
- Meta (United States) (US)
- Dana-Farber Cancer Institute (US)
- Virginia Cancer Specialists (US)
- ATUM (United States) (US)
- Grail (United States) (US)
- The US Oncology Network (US)
Publication Details
- Journal
- Cancer Prevention Research
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1158/1940-6207.capr-24-0468
- Citations
- 2
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Natera